Silvestris N - Search Results

1

Antineoplastic drug-induced bradyarrhythmias.

Minoia C, Giannoccaro M, Iacobazzi A, Santini D, Silvestris N, Fioretti A, Oliva S, Guarini A. Minoia C, et al. Among authors: silvestris n. Expert Opin Drug Saf. 2012 Sep;11(5):739-51. doi: 10.1517/14740338.2012.705826. Epub 2012 Jul 13. Expert Opin Drug Saf. 2012. PMID: 22788850 Review.

2

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.

Silvestris N, Tommasi S, Santini D, Russo A, Simone G, Petriella D, Maiello E, Tonini G, Colucci G. Silvestris N, et al. Expert Opin Biol Ther. 2009 May;9(5):565-77. doi: 10.1517/14712590902870394. Expert Opin Biol Ther. 2009. PMID: 19368524 Review.

3

The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma.

Silvestris N, Tommasi S, Petriella D, Santini D, Fistola E, Russo A, Numico G, Tonini G, Maiello E, Colucci G. Silvestris N, et al. Oncology. 2009;77 Suppl 1:69-74. doi: 10.1159/000258498. Epub 2010 Feb 2. Oncology. 2009. PMID: 20130434 Review.

4

Synchronous presentation of B-cell chronic lymphocytic leukemia/small-cell lymphoma and colon adenocarcinoma within the same mesenteric lymph nodes and a single liver metastasis.

Silvestris N, Zito FA, Fiore MG, Simone G, Tommasi S, Izzi G, Guarini A, Colucci G. Silvestris N, et al. J Clin Oncol. 2011 Jan 1;29(1):e11-3. doi: 10.1200/JCO.2010.31.1001. Epub 2010 Oct 12. J Clin Oncol. 2011. PMID: 20940198 No abstract available.

5

Adjuvant colon cancer chemotherapy: where we are and where we'll go.

Lombardi L, Morelli F, Cinieri S, Santini D, Silvestris N, Fazio N, Orlando L, Tonini G, Colucci G, Maiello E. Lombardi L, et al. Among authors: silvestris n. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S34-41. doi: 10.1016/S0305-7372(10)70018-9. Cancer Treat Rev. 2010. PMID: 21129608 Review.

6

Update on capecitabine alone and in combination regimens in colorectal cancer patients.

Silvestris N, Maiello E, De Vita F, Cinieri S, Santini D, Russo A, Tommasi S, Azzariti A, Numico G, Pisconti S, Petriella D, Lorusso V, Millaku A, Colucci G. Silvestris N, et al. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S46-55. doi: 10.1016/S0305-7372(10)70020-7. Cancer Treat Rev. 2010. PMID: 21129610 Review.

7

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A. Rizzo S, et al. Among authors: silvestris n. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9. Cancer Treat Rev. 2010. PMID: 21129611 Review.

8

Targeting EGFR in bilio-pancreatic and liver carcinoma.

Fratto ME, Santini D, Vincenzi B, Silvestris N, Azzariti A, Tommasi S, Zoccoli A, Galluzzo S, Maiello E, Colucci G, Tonini G. Fratto ME, et al. Among authors: silvestris n. Front Biosci (Schol Ed). 2011 Jan 1;3(1):16-22. doi: 10.2741/s128. Front Biosci (Schol Ed). 2011. PMID: 21196353 Free article. Review.

9

Oncosuppressor methylation: a possible key role in colon metastatic progression.

Tommasi S, Pinto R, Petriella D, Pilato B, Lacalamita R, Santini D, Zito F, Colucci G, Paradiso A, Silvestris N. Tommasi S, et al. Among authors: silvestris n. J Cell Physiol. 2011 Jul;226(7):1934-9. doi: 10.1002/jcp.22524. J Cell Physiol. 2011. PMID: 21506124

10

mTOR as a target of everolimus in refractory/relapsed Hodgkin lymphoma.

Guarini A, Minoia C, Giannoccaro M, Rana A, Iacobazzi A, Lapietra A, Raimondi A, Silvestris N, Gadaleta CD, Ranieri G. Guarini A, et al. Among authors: silvestris n. Curr Med Chem. 2012;19(7):945-54. doi: 10.2174/092986712799320727. Curr Med Chem. 2012. PMID: 22214465 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

380 results

Search Page